← H B Fuller overview

H B Fuller vs International Flavors & Fragrances: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

H B Fuller Company (FUL)

Q3 2026
▲2▼1

Fuller's profit jumps, AMS deal and Ancora bid reshape outlook

  • Strong profit growth and pricing Q2 profit rose 19% to $1.41 per share and Q3 profit jumped 21% to $1.52 per share, helped by 7.4% higher prices. All business units grew and profit margins expanded.

    This is the core positive driver of the quarter, showing broad-based earnings strength.

  • Advanced Medical Solutions acquisition Fuller is buying Advanced Medical Solutions for £715 million, moving into higher-growth medical adhesives. This expands its healthcare business and could boost future sales and profits.

    A major strategic move that shifts the company toward faster-growing markets.

  • Ancora's bid for Building Adhesives unit Activist investor Ancora raised its offer for Fuller's Building Adhesives unit to $1.4 billion. The public fight highlights that the unit may be undervalued, but it also creates uncertainty about the company's future structure.

    This event signals potential value but also introduces uncertainty, making it a mixed driver.

  • Rising debt and borrowing costs The AMS deal pushes debt to about 4 times earnings. Fuller also priced $850 million in 7.625% senior notes and refinanced $420 million, meaning higher interest costs that could squeeze future profits and increase financial risk.

    This is the main risk weighing on the stock, as higher debt and interest expenses could pressure earnings.

August 2026
▲1▼1

Fuller's profit engine hums, but debt and a buyout fight weigh

  • Q3 profit jumps 21% on pricing power Fuller's third-quarter profit rose 21% to $1.52 a share, beating estimates, as 7.4% price increases offset lower volumes. All three business units grew, and margins expanded. This shows the core adhesives business is getting stronger, which supports a higher stock price.

    This is the main new fundamental driver of FUL's value this period.

  • Ancora raises bid for building adhesives unit to $1.4B Activist Ancora lifted its cash offer for Fuller's Building Adhesives unit to as much as $1.4 billion, about half Fuller's market value, after the board rejected its earlier bid. The board says the unit is worth more. A sale could unlock value, but the public fight adds uncertainty.

    The raised bid is a major new event that could reshape the company and its stock.

  • AMS acquisition advances but adds debt risk Advanced Medical Solutions shareholders approved Fuller's £715 million purchase, moving the medical-adhesives deal closer to closing by year-end. It should boost long-term growth, but will push debt to about 4 times earnings, and analysts trimmed fair value on execution risk.

    The deal's progress and its balance-sheet impact are key new developments.

  • High-cost debt refinancing and new notes Fuller refinanced $420 million of loans and priced $850 million of 7.625% senior notes due 2034. The high interest rate signals lenders demand a premium, raising future interest costs and squeezing profits. This weighs on the stock by increasing financial risk.

    The expensive new debt is a fresh negative for FUL's finances.

Latest
▲1▼1

Fuller's profit engine hums, but debt and a buyout fight weigh

  • Q3 profit jumps 21% on pricing power Fuller's third-quarter profit rose 21% to $1.52 a share, beating estimates, as 7.4% price increases offset lower volumes. All three business units grew, and margins expanded. This shows the core adhesives business is getting stronger, which supports a higher stock price.

    This is the main new fundamental driver of FUL's value this period.

  • Ancora raises bid for building adhesives unit to $1.4B Activist Ancora lifted its cash offer for Fuller's Building Adhesives unit to as much as $1.4 billion, about half Fuller's market value, after the board rejected its earlier bid. The board says the unit is worth more. A sale could unlock value, but the public fight adds uncertainty.

    The raised bid is a major new event that could reshape the company and its stock.

  • AMS acquisition advances but adds debt risk Advanced Medical Solutions shareholders approved Fuller's £715 million purchase, moving the medical-adhesives deal closer to closing by year-end. It should boost long-term growth, but will push debt to about 4 times earnings, and analysts trimmed fair value on execution risk.

    The deal's progress and its balance-sheet impact are key new developments.

  • High-cost debt refinancing and new notes Fuller refinanced $420 million of loans and priced $850 million of 7.625% senior notes due 2034. The high interest rate signals lenders demand a premium, raising future interest costs and squeezing profits. This weighs on the stock by increasing financial risk.

    The expensive new debt is a fresh negative for FUL's finances.

July 2026
▲2

Fuller's profit beat and buyout battle reshape its path

  • Strong Q2 earnings and raised guidance Fuller's second-quarter profit rose 19% to $1.41 per share, revenue grew 5.8%, and the company raised its full-year profit outlook. This shows the core business is performing well, which supports a higher stock price.

    This is the main positive fundamental driver for FUL's price this period.

  • Acquisition of Advanced Medical Solutions Fuller agreed to buy Advanced Medical Solutions for £715 million, moving into higher-growth medical adhesives. The deal should boost long-term growth but will temporarily raise debt to about 4 times earnings, and an activist investor opposes it.

    This is a major strategic move that affects FUL's growth and risk profile.

  • Ancora's buyout offer for building adhesives unit Ancora offered $1.1–1.2 billion for Fuller's Building Adhesives Solutions unit, but the board rejected it as too low. The offer highlights the unit's value and could pressure management to unlock it, potentially lifting the stock.

    This event shows external interest in Fuller's assets and could lead to value creation.

▲2

Fuller's profit beat and buyout battle reshape its path

  • Strong Q2 earnings and raised guidance Fuller's second-quarter profit rose 19% to $1.41 per share, revenue grew 5.8%, and the company raised its full-year profit outlook. This shows the core business is performing well, which supports a higher stock price.

    This is the main positive fundamental driver for FUL's price this period.

  • Acquisition of Advanced Medical Solutions Fuller agreed to buy Advanced Medical Solutions for £715 million, moving into higher-growth medical adhesives. The deal should boost long-term growth but will temporarily raise debt to about 4 times earnings, and an activist investor opposes it.

    This is a major strategic move that affects FUL's growth and risk profile.

  • Ancora's buyout offer for building adhesives unit Ancora offered $1.1–1.2 billion for Fuller's Building Adhesives Solutions unit, but the board rejected it as too low. The offer highlights the unit's value and could pressure management to unlock it, potentially lifting the stock.

    This event shows external interest in Fuller's assets and could lead to value creation.

International Flavors & Fragrances Inc (IFF)

Q3 2026
▲3▼1

IFF's big portfolio overhaul and buyback drive the story

  • IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.

    This is the biggest strategic event of the period, reshaping IFF's business and capital returns.

  • Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.

    The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.

  • New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.

    Product launches show IFF's innovation pipeline and support future revenue growth.

  • Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.

    This reflects external validation of IFF's turnaround story and potential upside.

August 2026
▲3▼1

IFF's big portfolio overhaul and buyback drive the story

  • IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.

    This is the biggest strategic event of the period, reshaping IFF's business and capital returns.

  • Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.

    The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.

  • New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.

    Product launches show IFF's innovation pipeline and support future revenue growth.

  • Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.

    This reflects external validation of IFF's turnaround story and potential upside.

Latest
▲3▼1

IFF's big portfolio overhaul and buyback drive the story

  • IFF sells Food Ingredients for $3.8B and launches $2.5B buyback IFF agreed to sell its Food Ingredients unit to CVC for about $3.8 billion and announced a $2.5 billion share buyback, including a $500 million accelerated repurchase. This shrinks the company but sharpens focus on higher-margin Taste, Scent, and Health & Biosciences, and returning cash supports the stock.

    This is the biggest strategic event of the period, reshaping IFF's business and capital returns.

  • Q2 results miss and guidance cut on stranded costs IFF's Q2 revenue fell 29% to $1.95 billion and missed estimates badly, while full-year guidance was cut to $7.5 billion. Management blamed temporary stranded costs from the divestiture, but the miss and lower outlook weigh on investor confidence.

    The earnings miss and guidance cut are the main negative counterweight to the positive portfolio moves.

  • New product launches in scent and animal nutrition IFF launched SENSORA pro-fragrance technology, Omni-Bos PHY enzyme for dairy cattle, and AQUASCENT water-based fragrance carrier. These innovations target higher-margin growth areas and support the company's focus on R&D-led differentiation.

    Product launches show IFF's innovation pipeline and support future revenue growth.

  • Analysts and value funds see IFF as undervalued Morgan Stanley and Argus raised price targets, and Heartland Mid Cap Value Fund called IFF a deep-value opportunity trading at a discount to Givaudan. The new buyback and portfolio streamlining are seen as catalysts to close the valuation gap.

    This reflects external validation of IFF's turnaround story and potential upside.